KPIs & Operating Metrics(New)
Balance Sheet
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Current Deferred Revenue (2018 - 2024)

BioNTech SE's Current Deferred Revenue history spans 7 years, with the latest figure at $315.1 million for Q4 2024.

  • For Q4 2024, Current Deferred Revenue fell 17.1% year-over-year to $315.1 million; the TTM value through Dec 2024 reached $315.1 million, down 17.1%, while the annual FY2024 figure was $319.2 million, 16.48% down from the prior year.
  • Current Deferred Revenue for Q4 2024 was $315.1 million at BioNTech SE, down from $380.1 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $380.1 million in Q4 2023 and bottomed at $78.7 million in Q4 2022.
  • The 5-year median for Current Deferred Revenue is $315.1 million (2024), against an average of $268.8 million.
  • The largest annual shift saw Current Deferred Revenue plummeted 63.05% in 2022 before it surged 383.25% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $357.2 million in 2020, then tumbled by 40.4% to $212.9 million in 2021, then plummeted by 63.05% to $78.7 million in 2022, then soared by 383.25% to $380.1 million in 2023, then decreased by 17.1% to $315.1 million in 2024.
  • Per Business Quant, the three most recent readings for BNTX's Current Deferred Revenue are $315.1 million (Q4 2024), $380.1 million (Q4 2023), and $78.7 million (Q4 2022).